OKYO Pharma OKYO

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for inflammatory eye diseases and ocular pain. Operating in the ophthalmology sector, the company targets high-unmet medical needs by leveraging novel G Protein-Coupled Receptor (GPCR) biology, specifically the ChemR23 receptor, which plays a critical role in ocular inflammation and pain modulation. OKYO Pharma’s research and development efforts are centered on advancing drug candidates through clinical trials, with a primary emphasis on addressing conditions such as neuropathic corneal pain (NCP) and dry eye disease (DED).

The company generates revenue through the potential future commercialization of its lead drug candidate, urcosimod, and other pipeline assets. Currently, OKYO Pharma does not derive revenue from product sales, as its candidates remain in clinical development. Instead, the company’s financial model relies on milestone payments tied to regulatory and developmental progress, as well as potential licensing agreements, partnerships, or eventual product sales upon regulatory approval. The intellectual property portfolio, including patents and pending applications, further underpins the company’s long-term revenue prospects by securing exclusivity for its therapeutic innovations.

The company operates through the following segments.

• Ocular Therapeutics: This segment focuses on the development of urcosimod, a lipidated peptide designed to target the ChemR23 receptor to alleviate ocular pain and inflammation. The candidate is being evaluated in clinical trials for neuropathic corneal pain (NCP), a condition with no FDA-approved treatments, and dry eye disease (DED). The segment also includes preclinical exploration of OK-201, a non-opioid analgesic for ocular pain, though development efforts are currently secondary to urcosimod.

OKYO Pharma occupies a niche position within the ophthalmology industry, targeting underserved markets with high unmet medical needs. The company’s lead candidate, urcosimod, addresses neuropathic corneal pain, a debilitating condition lacking approved therapies, positioning OKYO Pharma as a potential first-mover in this space. In dry eye disease, the company competes with established players such as Allergan, Novartis, and Sun Pharmaceuticals, which offer approved treatments like Restasis, Xiidra, and Cequa. However, OKYO Pharma’s competitive advantage lies in its novel mechanism of action, targeting the ChemR23 receptor to modulate both inflammation and pain, a dual approach that distinguishes it from existing therapies. The company’s intellectual property portfolio, including patents extending into the 2030s and 2040s, further strengthens its market position by providing long-term exclusivity for its innovations.

The company’s customer base primarily consists of patients suffering from inflammatory eye diseases and ocular pain, particularly those with neuropathic corneal pain and dry eye disease. Clinical trials and future commercialization efforts target ophthalmologists, cornea specialists, and healthcare providers treating these conditions. While no specific customer names are disclosed, the company collaborates with leading academic and medical institutions, such as Tufts Medical Center, to advance its clinical programs. These partnerships enhance the credibility and scientific rigor of OKYO Pharma’s development efforts, positioning the company to serve a broad patient population upon regulatory approval.